PharVision Advisers’s Haemonetics HAE Stock Holding History

PharVision Advisers’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,537	Closed	-$283K	–	339
2025 Q4	$283K	Buy	+3,537	New	+$238K	0.14%	308

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PharVision Advisers's HAE Position: Q1 2026 in Review

PharVision Advisers sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 3,537 shares — an estimated $283K sold.

PharVision Advisers first reported a position in HAE in Q4 2025 and held it in 1 quarter. The position peaked at $283K in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

PharVision Advisers reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,537 Haemonetics shares in Q1 2026, an estimated $283K.
PharVision Advisers first reported a position in Haemonetics in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Haemonetics position peaked at $283K in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.